There are currently no studies to support the use of Ceftazidime/amikacin-based regimen as first choice empirical treatment in patients with neutropenic fever.Demonstrate that the caftazidime/amikacin regimen is not the best empirical therapeutic approach, and could be directly impacting on longer recovery time, longer hospital stay, higher costs.
Bitte wählen Sie Ihr Anliegen aus.
Rechnungen
Retourenschein anfordern
Bestellstatus
Storno